Evoke Pharma, Inc. (EVOK)
After hours: 04:00PM EDT
| Previous close | 1.2500 |
| Open | 1.2400 |
| Bid | 1.2200 x 1100 |
| Ask | 1.2900 x 1100 |
| Day's range | 1.2146 - 1.2600 |
| 52-week range | 0.9600 - 4.8000 |
| Volume | 17,297 |
| Avg. volume | 497,806 |
| Market cap | 40.874M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings date | 08 Nov 2021 - 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
- GlobeNewswire
Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study
Evoke Pharma, Inc. Trend Across Waves for Proportion of Respondents Who Are Highly Familiar With GIMOTI (score of 4 or 5 out of 5) Health care practitioners’ perception of nasal route of administration similar to IV; 92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in Las Vegas, October 22-27, 2021 SOLANA BEACH, Calif. and CHICAGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company foc
- GlobeNewswire
Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI
Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis SOLANA BEACH, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life sciences industry, today announced that PM360, a publication for marketing decision makers
- Simply Wall St.
Evoke Pharma (NASDAQ:EVOK) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
